Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
US10954299B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 24, 2017 |
| Grant date | Mar 23, 2021 |
| Priority date | — |
| Expiry date | May 24, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or/and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.